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S U M M A R Y
Lyme disease is a multisystem disease that frequently affects children. It is caused by a group of related
spirochetes, Borrelia burgdorferi sensu lato, that are transmitted by ticks belonging to species of the genus
Ixodes. The clinical characteristics of Lyme disease in pediatrics resemble those observed in adults,
although the symptoms may last for a shorter time and the outcome may be better. However, identifying
Lyme disease in children can be signiﬁcantly more difﬁcult because some of its signs and symptoms can
be similar to those of other common pediatric clinical manifestations. Finally, the diagnostic and
therapeutic approach to childhood Lyme disease is frequently not codiﬁed, and guidelines speciﬁcally
prepared for adults are used for children without having been validated. This review of the currently
available data will evaluate what may be the best approach to the diagnosis and treatment of B.
burgdorferi infection and disease in the pediatric population.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Lyme disease is a multisystem disease caused by a group of
related spirochetes, Borrelia burgdorferi sensu lato, that are
transmitted by ticks belonging to some species of the genus
Ixodes.1 The ticks become infected with B. burgdorferi while feeding
on the blood of natural reservoir hosts such as mice, squirrels,
shrews, and other small vertebrates.1 During subsequent blood
meals, the ticks can transmit infection among reservoir or
incidental hosts, including humans. Moreover, although not
infected by B. burgdorferi, other mammals such as deer can play
a role in transporting and maintaining tick populations.1
The risk of Lyme disease is related to tick abundance and
exposure,2,3 and so it has a higher incidence among subjects living in
rural areas, forestry and farm workers, hunters, mushroom
gatherers, and berry pickers. Moreover, most infections occur in
the spring, summer, and early autumn, when the ticks are in the
nymph stage and people are more likely to be active. Lyme disease
has been diagnosed throughout the world, but the most important
epidemiological studies have been carried out in the USA and
Europe.2,3 In the USA, during the period 1992–2006 a total of 248 074
cases of Lyme disease were reported to the Centers for Disease
Control and Prevention (CDC), with an incidence across the whole
country of 13.4 per 100 000 inhabitants. However, 93% of the* Corresponding author. Tel.: +39 02 55032498; fax: +39 02 50320206.
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Massachusetts, Maryland, Minnesota, New Jersey, New York,
Pennsylvania, Rhode Island, and Wisconsin) where the incidence
was signiﬁcantly higher. This highlights the fact that the geographic
distribution of cases is highly focused, with the majority of reported
cases occurring in the northeastern and north-central states of the
USA.2 In Europe, where the main endemic areas are located in
Scandinavia and the southern part of central Europe (Germany,
Austria, north-east Italy, and Slovenia), the reported incidence is
more than 300 cases per 100 000 inhabitants.4 Children are among
the subjects at highest risk of Lyme disease,2–4 which has a bimodal
age distribution with peak incidence rates among children aged 5–9
years and adults aged 45–59 years.2
In general, the clinical characteristics of childhood and adult
Lyme disease are similar, except for meningopolyradiculoneuritis
and acrodermatitis chronica atrophicans, which are manifestations
typically not seen in children. There is also evidence indicating that
children experience shorter-lasting symptoms and have better
outcomes.5 However, Lyme disease can be signiﬁcantly more
difﬁcult to identify in children because some of its signs and
symptoms are similar to those of other diseases that are quite
common in the ﬁrst years of life.5 Finally, the diagnostic and
therapeutic approach to pediatric Lyme disease is frequently not
codiﬁed, and guidelines speciﬁcally prepared for adults are used
for children without having been validated. The aim of this review
of the currently available data is to evaluate what may be the best
approach to the diagnosis and treatment of B. burgdorferi infection
and disease in the pediatric population.ses. Published by Elsevier Ltd. All rights reserved.
Figure 1. Primary erythema migrans in a 7-year-old Italian child.
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Little is known about the real incidence of asymptomatic B.
burgdorferi infection, although it has been shown that the
seroprevalence of B. burgdorferi IgG antibodies in the general
population varies from 2% and 26% depending on age, season,
geographical area, and laboratory methods.5 The reported sero-
prevalence in children ranges from 2.6% to 15%.5–7 As very few
seropositive patients have reported previous symptoms or
treatment for Lyme disease, it has been believed that B. burgdorferi
infections may have an asymptomatic course in a large number of
children.
However, these data are widely debated because a number of
studies have determined antibody titers by means of immunoﬂu-
orescence (IF) assays or by enzyme-linked immunosorbent assays
(ELISAs) without conﬁrming reactive specimens by means of
Western immunoblotting (WI). This is a considerable limitation
because the speciﬁcities of both IF and ELISA are low, and their use
can lead to an overestimate of the incidence of asymptomatic B.
burgdorferi infection.8
Only two-tier testing (IF or ELISA and WI of positive cases) can
allow a more precise deﬁnition of the real incidence of
asymptomatic B. burgdorferi infection.9 Adult data show that it
can increase speciﬁcity to 99%, but unfortunately there are no
pediatric data and so it is not known whether the sensitivity and
speciﬁcity of two-tier testing are as high in children as in adults. On
the other hand, children and adults have different immune
responses to B. burgdorferi: in adults, the immune response is
characterized by a strong Th1 response with high numbers of B.
burgdorferi-speciﬁc interferon (INF)-g-secreting cells and low
levels of interleukin (IL)-4, whereas children seem to have a more
balanced immune response with elevated secretion of both IFN-g
and IL-4.10
3. Skin manifestations
3.1. Erythema migrans
Primary erythema migrans (EM) is the most common clinical
manifestation of B. burgdorferi infection. It affects people of all ages
and both genders and can be diagnosed in up to 89% of patients
with Lyme disease.11 This ﬂat red skin lesion (Figure 1) develops at
the site of the tick bite (frequently the axilla, groin, or thigh)
approximately 7–14 days (range 3–30 days) after the insect has
detached or been removed. In adult patients, EM is most often
located on the legs and feet; in children, the upper part of the body
is more frequently affected.12 EM is often accompanied by fever,
chills, and myalgia, and subsequently tends to expand, often with
central clearing. The proportion of patients with systemic
symptoms is higher in the USA than in Europe. In 30–50% of the
cases, the lesions increase in number as a result of the early
dissemination of B. burgdorferi.13 All the signs and symptoms of the
disease, including the skin lesions, usually disappear spontane-
ously after about 1 month.
B. burgdorferi bacteremia has been detected in 7.6% of children
with primary EM and in 15.8% of those with multiple skin lesions;
in untreated cases, it can persist for up to 39 days after the onset of
the skin rash.13 In adults, it was reported in about 14% of patients
with EM.14
European patients with EM are more frequently seronegative
for B. burgdorferi, whereas most American patients are seroposi-
tive. Epidemiological studies have reported positive IgM and/or IgG
antibodies against the pathogen in 5–37% of patients with a
solitary EM and 22–89% of those with multiple EM.9,11 However,
independent of antibody positivity, medical laboratory tests do not
show signs of inﬂammation or any other abnormalities.Consequently, the diagnosis of EM is mainly clinical, and for
atypical lesions the presence of the pathogen in the skin needs to
be proven. Differences between the studies are probably related to
antigenic differences among the B. burgdorferi species causing the
disease (EM is most often caused by Borrelia afzelii in Europe and by
Borrelia burgdorferi sensu stricto in the USA), differences in
laboratory detection methods, and the use of antibiotics or no
treatment. However, it needs to be stressed that IgM antibodies are
undetectable until 2–3 weeks after the appearance of skin lesions,
and IgG antibodies can only be detected after 4 weeks. The long
time before laboratory test results become available and the low
speciﬁcity of the tests themselves explain why most experts do not
suggest immunological tests for the diagnosis of EM, but believe it
is enough to know that a child lives in an endemic area and has one
or more of the characteristic skin lesions.4
The administration of antibiotics is suggested by all health
authorities when EM is highly suspected. Regimens suggested in
the USA for children are based on those indicated for adults: they
include amoxicillin or doxycycline (for patients aged >8 years) or
cefuroxime axetil as ﬁrst-line therapy, and exclude macrolides
from the group of ﬁrst-line drugs.15 However, two randomized
clinical trials carried out in Slovenia have shown that, in the case
of a solitary EM, the administration of oral phenoxymethylpeni-
cillin (100 000 IU/kg/day in three doses for 14 days), oral
amoxicillin (50 mg/kg/day in three doses for 14 days), or oral
cefuroxime axetil (30 mg/kg/day in two doses for 14 days) is as
effective as oral azithromycin (20 mg/kg for the ﬁrst day, followed
by 10 mg/kg/day in a single dose for a further 4 days) in delivering
a favorable clinical outcome.16,17 EM disappeared in 3–4 days in
all of the treatment groups, only 10–15% of the children developed
minor manifestations of Lyme disease during treatment, and the
number of major manifestations was marginal during the year
following treatment. This suggests that the appropriate antibiotic
treatment of EM can reduce the risk of the complications of B.
burgdorferi infection.
Table 1
Risk of pediatric Lyme meningitis
Rule of seven clinical predictors Percentage
with LM
Headache for 7 days 52
Cranial nerve palsy 70
CSF mononuclear cells 70% 38
Headache for 7 days and cranial nerve palsy 72
Headache for 7 days and CSF mononuclear cells 70% 53
Cranial nerve palsy and CSF mononuclear cells 70% 74
Headache for 7 days, cranial nerve palsy, and
CSF mononuclear cells 70%
77
From Cohn et al.,32 modiﬁed. CSF, cerebrospinal ﬂuid; LM, Lyme meningitis.
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Borrelial lymphocytoma is a solitary bluish-red swelling with a
diameter of up to a few centimeters, consisting of a dense
lymphocytic inﬁltration of cutis and subcutis. The inﬁltration is
polyclonal with a predominance of B lymphocytes, and often
shows germinal centers.18 The lesion is most frequently located on
the earlobe in children, and in the region of the areola mammae in
adults. This rare manifestation arises later and is of longer duration
than EM, but also resolves spontaneously. Most borrelial lympho-
cytomas arise in the vicinity of a previous or concurrent EM lesion.
Histological examination is needed in patients with lymphocy-
toma at a location other than the ear lobe.18
3.3. Neuroborreliosis
Although it occurs in only a few cases, the invasion of a child’s
nervous system by B. burgdorferi can cause facial palsy and
meningitis (the most common clinical manifestation of pediatric
neuroborreliosis), myoclonus, ataxia, vertigo, trochlear palsy,
cranial polyneuritis, acute transverse myelitis with hemiparesis,
or idiopathic intracranial hypertension.18,19 In contrast to adult
Lyme disease patients, Bannwarth’s syndrome (meningoradiculi-
tis) and mild radiculoneuritis are uncommon and encephalopathy
is rare.19 Neurological involvement is considered an early
manifestation of disseminated Lyme disease because it usually
occurs only some weeks after a tick bite.
Historically, the most frequently identiﬁed cause of facial palsy
in children is otitis media;19 however, over the last 20 years, there
has been a signiﬁcant increase in the incidence of facial palsy
associated with B. burgdorferi infection and, at least in endemic
areas, Lyme disease has become the major cause.19 Studies carried
out in Scandinavia20 and the USA19,21 have found that Lyme disease
was the cause of 34–65% of facial palsy cases, with the highest rates
among children living in hyperendemic regions. Facial palsy occurs
in about 5% of the children with Lyme disease.11,22–24 In many
cases, it may be the only neurological abnormality and can develop
even in the absence of previous EM.
It is critical to identify the children suffering from Lyme disease
at the time of the initial evaluation of a case of facial palsy because
appropriate therapy depends on identifying its etiology. In the case
of Bell’s palsy (the second most frequent type of facial palsy),
corticosteroids and antivirals have been suggested as possible
treatments, but there is insufﬁcient evidence to demonstrate the
efﬁcacy of either.24,25 In the case of facial palsy associated with
Lyme disease, antibiotic therapy for 14 days is generally
recommended, although there is still considerable controversy
as to whether it should be administered orally or parenterally.15
Clinical and laboratory data are frequently of no etiological help
in the absence of other clinical manifestations, or if the facial palsy
is seen within the ﬁrst days of presentation, when laboratory test
results are not available or still negative. However, Nigrovic et al.
have shown that the onset of facial palsy during the peak Lyme
disease season, the absence of previous herpetic lesions, the
presence of fever, and a history of headache might be considered
independent clinical predictors of Lyme disease in children with
facial palsy.23 They have therefore suggested that children with
one or more high-risk predictors of Lyme disease should undergo a
complete laboratory examination for B. burgdorferi infection, and
that starting an empiric antibiotic treatment based on oral
amoxicillin (50 mg/kg/day in three doses) or cefuroxime axetil
(30 mg/kg/day in two doses), or for those aged >8 years
doxycycline (4 mg/kg/day in two doses), should be carefully
considered.15
Other prognostic factors have recently been identiﬁed that
increase the possibility of precisely deﬁning the etiology of facialpalsy and prescribing appropriate therapy. Fine et al. have shown
that the accuracy of a diagnosis of Lyme disease can be signiﬁcantly
increased if the geographical incidence of B. burgdorferi infection is
integrated with previously identiﬁed prognostic factors.26 More-
over, Bremell and Hagberg found that high cerebrospinal ﬂuid
(CSF) levels of mononuclear cells and albumin strongly predict B.
burgdorferi infection as the cause of peripheral facial palsy in a
highly endemic area.27 This ﬁnding has led some authors to
suggest systematically examining the CSF of all children with facial
palsy living in endemic areas.15
Regarding long-term outcomes, there is widespread concern
about the possible neurological sequelae of facial palsy associated
with Lyme disease. A number of studies of adults have indicated
that there may be adverse cognitive effects, particularly in terms of
short- and long-term memory, intelligence, information proces-
sing speed, ﬁne motor dexterity, problem solving, and new
learning.28,29 However, studies of children with facial palsy
attributable to Lyme disease seem to indicate that the neuropsy-
chological and health outcomes are good and no different from
those of children without Lyme disease.28,29 This could suggest
that in children with facial palsy in whom the disease can be
ascribed to B. burgdorferi infection because of an association with
either EM or a positive serology, direct CSF examination could be
avoided.
Lyme meningitis (LM) is diagnosed in about 2% of children with
Lyme disease,10 and has a 13% prevalence among all forms of
aseptic meningitis diagnosed in a borreliosis-endemic region
during the peak period of Lyme disease.30 Like aseptic meningitis,
LM is characterized by signs and symptoms that are quite similar to
those observed in the case of viral meningitis. The early recognition
of LM while awaiting the results of serological tests is important
because adequate antibiotic treatment decreases its acute and
long-term symptoms.31 On the basis of previous experience,
children with <7 days of headache, <70% mononuclear cells in CSF,
and the absence of 7th (or other) cranial nerve palsy are currently
classiﬁed as having a low risk of LM in the USA (Table 1).32,33 In
Europe a different predictive model has been developed by
Tuerlinckx et al.34 on the basis of four variables: the duration of
symptoms before admission, the presence of cranial neuropathy,
the CSF concentration of proteins (all of which are more frequent or
higher in children with LM), and the percentage of neutrophil cells
in the CSF (lower in cases of LM).34
The suggested treatment of LM is based on the use of
ceftriaxone (50–75 mg/kg/day in a single daily intravenous (IV)
dose) for 14 days. An alternative is cefotaxime (150–200 mg/kg/
day in three or four IV doses) or penicillin G (200 000–400 000
units/kg/day IV in six doses). Patients aged >8 years have also been
successfully treated with oral doxycycline 4–8 mg/kg/day in two
doses.15 In most cases, all of these treatments have led to the
complete resolution of symptoms and signs of disease. In only one
Swedish study, six out of 40 children reported sequelae (three
cases of residual facial palsy and three of ataxia, both associated
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of these children were treated with IV penicillin, whereas those
receiving doxycycline or penicillin plus doxycycline did not report
the persistence of any neurological abnormalities.
4. Heart borreliosis
Adult data indicate that 4–10% of subjects with Lyme disease
develop carditis, with transient disturbances in atrioventricular
conduction being the main clinical ﬁnding, probably due to the
direct invasion of cardiac tissue by spirochetes and the conse-
quent inﬂammatory response.36 More recently, collected data
seem to indicate that heart involvement in adults is decreasing,
perhaps because of improved recognition of early localized Lyme
disease. However, the incidence in children has not yet been
precisely deﬁned. Different studies have found rates varying from
<1% to 16%, with the highest rates occurring when cardiac
involvement was systematically evaluated by means of at least
one electrocardiogram, or when selected samples of patients were
studied.37 The importance of selection bias in determining the
incidence of heart disease in children is clearly demonstrated by
the study of Costello et al.37 In this large study, the authors
examined only patients with early disseminated Lyme disease and
found that among 207 cases, 33 had carditis (15.9%), and of these,
14 (42%) had an advanced heart block, including nine (27%) with a
complete block.37 Most of the cases were treated with ceftriaxone
for 3–4 weeks, which led to the recovery of sinus rhythm in a mean
of 3 days (range 1–7 days); none required a permanent
pacemaker. Four of the 33 patients with carditis (12%) had
depressed systolic ventricular function, three of whom (9%)
required mechanical ventilation, temporary pacing, and inotropic
support. Carditis was more likely in children aged >10 years and
those with arthralgias or cardiopulmonary symptoms.37 On the
basis of these ﬁndings, the authors suggested that the threshold
for obtaining an electrocardiogram in children with possible early
disseminated Lyme disease should be particularly low in older
children, those with arthralgias, and especially those with
cardiopulmonary symptoms. After starting antibiotic therapy,
children with initially prolonged PR intervals (but <300 ms)
should undergo repeat electrocardiography within 1–2 days. The
children with initial PR intervals of 300 ms are more likely to
develop a high-grade atrioventricular block and warrant teleme-
try monitoring in a hospital capable of providing temporary
transvenous pacing. However, after therapy, the advanced heart
block usually resolves within 1 week.
5. Lyme arthritis
Lyme arthritis (LA) is a late manifestation of Lyme disease
characterized by intermittent, recurring, pauciarticular attacks of
joint swelling and pain that persist for days or months.38 It occurs
in 50–60% of untreated patients. Children are more likely to
develop arthritis secondary to B. burgdorferi infection than adults,
and are also more likely to have arthritis as the sole presenting
symptom of disease.39
The clinical picture of LA frequently resembles that of septic
arthritis and juvenile rheumatoid arthritis (JRA), with laboratory
evidence of inﬂammation and with a high leukocyte count in
synovial ﬂuid.40 Most patients do not recall a preceding tick bite,
which means that LA cannot be easily differentiated from the
other most common forms of pediatric arthritis at presentation.
On the other hand, a prompt diagnosis is essential because each of
these diseases requires a speciﬁc therapy, and a delay in treatment
can lead to negative consequences. Unfortunately, as in the case of
facial palsy and meningitis, B. burgdorferi serology cannot be used
to make an early diagnosis of LA because the test results can takedays to arrive. Moreover, although more sensitive than cultures,
molecular methods for detecting B. burgdorferi in synovial ﬂuid
are difﬁcult to use, have a yield that strictly depends on the
primer–probe set, and are conditioned by previous antibiotic
therapy.39,40 Consequently, various attempts have been made to
formulate clinical diagnostic aids. Thompson et al. recently
compared patients with LA and septic arthritis and found that
the erythrocyte sedimentation rate, C-reactive protein levels, and
joint white blood cell counts and neutrophil percentages were
statistically lower in the former.40Moreover, the children with LA
were more likely to have a history of tick bites and knee
involvement, and less likely to have a history of fever or a high
temperature at triage.40 However, the overlapping of many
clinical parameters did not allow the accurate differentiation of
LA.
It has been demonstrated that most adult cases of LA resolve
without sequelae after 4 weeks of oral antibiotic treatment, 10%
have persistent arthritis that requires a second course of oral or
parenteral antibiotics or both, and 1–3% of these develop refractory
disease requiring treatment with intra-articular steroids, syno-
vectomy, or immunomodulating agents.39 Outcomes in children
are less well deﬁned because of the paucity of pediatric studies and
the fact that the patients in case series have been treated in
different ways, but seem to be better than adult outcomes. Szer
et al. studied the long-term course of LA in 46 children who
received no antibiotic therapy for at least the ﬁrst 4 years of the
illness.41 In most cases, the initial symptoms were followed by
brief attacks of arthritis, particularly affecting the knee. The
percentage of children with recurrent episodes of arthritis
decreased each year and, by the end of the fourth year, only 10
children still had a mean of two annual episodes. However, during
the sixth year of illness, two children (4%) had keratitis and, more
than 10 years after disease onset, two other children developed
subtle encephalopathy, thus suggesting that untreated LA can be
associated with the development of ocular and brain diseases.
Antibiotic treatment seems to modify the natural course of LA
profoundly.42 Tory et al., following 99 children with LA, found that
75% of the cases resolved with antibiotic therapy, and none of the
patients with antibiotic-refractory arthritis for whom follow-up
data were available developed chronic arthritis, joint deformities,
or recurrent infections.43
6. Vertical infection of the fetus
The transplacental passage of causative agents from the
infected mother to the offspring resulting in an adverse outcome
has been acknowledged in several spirochetal diseases such as
syphilis, relapsing fever, and leptospirosis.44 The corresponding
information for Lyme borreliosis is limited. Although the in utero
transmission of B. burgdorferi during pregnancy resulting in fetal
involvement has been reported,45,46 the information is restricted to
a description of single cases, in some of which the proof of borrelial
infection is uncertain. However, in pregnant women it is
particularly important to recognize the disease early so that
effective therapy can be instituted. No comparative studies on the
effectiveness of different therapeutic approaches are available.
Treatment results on large series of pregnant women with Lyme
disease are limited to therapy with intravenous ceftriaxone. With
this approach, a favorable course and outcome of borrelial
infection in pregnant women, and a good outcome for their
pregnancies, have been achieved.47
7. Prevention of B. burgdorferi infection
B. burgdorferi infection can be prevented by avoiding tick-
infected environments and, when in such environments, by
Table 2
Reactivities obtained using different methods for detecting antibodies to Borrelia burgdorferi in Lyme disease
Test % Reactivity in patients with:
EM, acute phase EM, convalescent phase Neuroborreliosis Lyme arthritis
ELISA 33–49 76–86 79 100
IgM WB 43–44 75–84 80 16
IgG WB 0–13 15–21 64–72 96–100
Two-tier testing 29–40 29–78 87 97
From Aguero-Rosenfeld et al.,9 modiﬁed. ELISA, enzyme-linked immunosorbent assay; EM, erythema migrans; WB, Western blot.
Table 3
Suggested treatment of pediatric Lyme disease
Clinical manifestation Drug Dose Duration
Erythema migrans Preferred
Amoxicillin 50 mg/kg/day orally in three doses 14 days
Cefuroxime axetil 30 mg/kg/day orally in two doses 14 days (10–21 days)
Doxycycline In children aged >8 years, 4 mg/kg/day orally in two doses 14 days
Alternative
Azithromycin 20 mg/kg/day orally on day 1, followed by 10 mg/kg/day
orally on days 2–5
5 days
Clarithromycin 15 mg/kg/day orally in two doses 14 days (10–21 days)
Erythromycin 50 mg/kg/day orally in four doses 14 days (10–21 days)
Neuroborreliosis Preferred
Ceftriaxone 50–75 mg/kg/day IV in one dose 14 days (10–30 days)
Alternative
Cefotaxime 150–200 mg/kg/day IV in three doses 14 days (10–30 days)
Doxycycline In children aged >8 years, 4–8 mg/kg/day orally in two doses 21 days (10–30 days)
Penicillin G 200 000–400 000 IU/kg/day IV in six doses 14 days (10–30 days)
Heart borreliosis Ceftriaxone 50–75 mg/kg/day IV in one dose 14 days (10–30 days)
Lyme arthritis Amoxicillin 50 mg/kg/day orally in three doses 28 days
Cefuroxime axetil 30 mg/kg/day orally in two doses 28 days
Doxycycline In children aged >8 years, 4 mg/kg/day orally in two doses 28 days
IV, intravenous.
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skin or clothing.48 Attached ticks should be removed as rapidly as
possible because the transmission of B. burgdorferi infection
usually occurs only after several hours. On the other hand, not
all ticks are infected and, even when they are, transmission does
not occur in all subjects. Fryland et al. studied subjects bitten by
ticks in an area with a high incidence of Lyme disease, and found
that only 75/397 ticks were B. burgdorferi-positive, and only 1/64
subjects bitten by B. burgdorferi-infected ticks developed symp-
toms of Lyme disease in the following 3 months.48 Systematic
antibiotic prophylaxis can further reduce the risk of developing
Lyme disease after tick removal.49 Although the pediatric data are
few and inconclusive, on the basis of what has been demonstrated
in or suggested for adults, older children could receive a single dose
of oral doxycycline (200 mg), whereas those younger than 8 years
could be treated with a 10-day course of oral amoxicillin (50/mg/
kg/day).49 No vaccine is currently available.
8. Conclusions
Although Lyme disease has become more common over recent
years and children are among the more frequently affected
subjects, there are still problems concerning the identiﬁcation
and treatment of young patients infected by B. burgdorferi. In most
cases, the diagnostic and therapeutic approach is simply based on
the methods used for adults, even though they have not been
validated in pediatric populations (Tables 2 and 3). This may lead
to an overestimate of the number of children thought to be infected
by B. burgdorferi and a greater than necessary use of invasive and
noninvasive treatments.
Many aspects of B. burgdorferi infection are still unclear, and
further pediatric studies are needed. A precise evaluation of the
immune responses of younger patients to B. burgdorferi is requiredin order to understand whether the laboratory tests used to
identify infected adult cases are similarly sensitive and speciﬁc in
children. It is only when this has been clariﬁed that it will be
possible to identify those children who really need antibiotic
therapy for suspected Lyme disease. Moreover, antibiotic regimens
need to be evaluated by means of speciﬁc randomized and blinded
pediatric clinical trials in order to rationalize the choice of the
drugs and the dose and the duration of their administration.
Finally, greater knowledge of the antigenic characteristics of each
B. burgdorferi species and the host immune response to each
antigen could lead to the formulation of effective vaccines.
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